Rapacuronium

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Rapacuronium
Rapacuronium bromide.svg
Rapacuronium bromide
Clinical data
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Intravenous
ATC code
  • none
Legal status
Legal status
  • US: Withdrawn
Pharmacokinetic data
Bioavailability Not applicable
Protein binding Variable
Metabolism Hydrolyzed to active metabolites
CYP system not involved
Biological half-life 141 minutes (mean)
Excretion Renal and fecal
Identifiers
Synonyms [(2S, 3S, 5S, 8R, 9S, 10S, 13S, 14S, 16S, 17S)-3-acetyloxy-10,13-dimethyl-2-(1-piperidyl)-16-(1-prop-2-enyl-3,4,5,6-tetrahydro-2H-pyridin-1-yl)-2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,11 ,12 ,14, 15, 16, 17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]propanoate
CAS Number
PubChem CID
DrugBank
ChemSpider
ChEMBL
ECHA InfoCard 100.211.226
Chemical and physical data
Formula C37H61N2O4+
Molar mass 597.891 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Rapacuronium (Raplon) is a rapidly acting, non-depolarizing neuromuscular blocker formerly used in modern anaesthesia, to aid and enable endotracheal intubation, which is often necessary to assist in the controlled ventilation of unconscious patients during surgery and sometimes in intensive care. As a non-depolarizing agent it did not cause initial stimulation of muscles before weakening them.

Due to risk of fatal bronchospasm it was withdrawn from the United States market by Organon on March 27, 2001, less than 2 years after its FDA approval in 1999.[1]

References[edit]

  1. ^ Shapse, Deborah (March 27, 2001). "Voluntary Market Withdrawal" (PDF).  (10.8 KiB). Organon International. Retrieved on 2007-04-02.